Artelo Biosciences annual operating expenses
2014
2015
2016
2017
2018
2019
2020
2021
2021
2022
2023
2024
2025
Artelo Biosciences Operating Expenses Growth & History (ARTL)
Artelo Biosciences's operating expenses was $11.4M for fiscal 2025.
View full Artelo Biosciences company overviewArtelo Biosciences annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $11.4M | $1.3M | +12.82% |
| 2024 | 2024-12-31 | $10.1M | $178,000 | +1.79% |
| 2023 | 2023-12-31 | $9.9M | −$357,000 | −3.47% |
| 2022 | 2022-12-31 | $10.3M | $870,000 | +9.24% |
| 2021 · Dec 31 | 2021-12-31 | $9.4M | — | — |
| 2021 · Aug 31 | 2021-08-31 | $7.4M | $2.8M | +58.79% |
| 2020 | 2020-08-31 | $4.7M | $1.5M | +46.00% |
| 2019 | 2019-08-31 | $3.2M | $866,040 | +36.96% |
| 2018 | 2018-08-31 | $2.3M | $2.1M | +906.70% |
| 2017 | 2017-08-31 | $232,789 | $203,099 | +684.07% |
| 2016 | 2016-08-31 | $29,690 | $14,449 | +94.80% |
| 2015 | 2015-08-31 | $15,241 | −$28 | −0.18% |
| 2014 | 2014-08-31 | $15,269 | — | — |
Artelo Biosciences quarterly operating expenses
Q2.14
Q3.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q2.21
Q3.21
Q3.21
Q3.21
Q1.22
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.5M | −$645,000 | −20.48% |
| Q1 2026 | 2026-03-31 | $2.7M | $310,000 | +13.03% |
| Q4 2025 | 2025-12-31 | $2.8M | −$1.0M | −26.92% |
| Q3 2025 | 2025-09-30 | $3.1M | $1.9M | +158.49% |
| Q2 2025 | 2025-06-30 | $3.1M | $638,000 | +25.40% |
| Q1 2025 | 2025-03-31 | $2.4M | −$210,000 | −8.11% |
| Q4 2024 | 2024-12-31 | $3.8M | $572,000 | +17.65% |
| Q3 2024 | 2024-09-30 | $1.2M | −$1.4M | −54.28% |
| Q2 2024 | 2024-06-30 | $2.5M | $728,000 | +40.81% |
| Q1 2024 | 2024-03-31 | $2.6M | $297,000 | +12.96% |
| Q4 2023 | 2023-12-31 | $3.2M | −$236,000 | −6.79% |
| Q3 2023 | 2023-09-30 | $2.6M | $220,000 | +9.19% |
| Q2 2023 | 2023-06-30 | $1.8M | −$687,000 | −27.80% |
| Q1 2023 | 2023-03-31 | $2.3M | $346,000 | +17.78% |
| Q4 2022 | 2022-12-31 | $3.5M | — | — |
| Q3 2022 | 2022-09-30 | $2.4M | $149,000 | +6.64% |
| Q2 2022 | 2022-06-30 | $2.5M | $217,000 | +9.63% |
| Q1 2022 · Mar 31 | 2022-03-31 | $1.9M | $250,000 | +14.74% |
| Q1 2022 · Nov 30 | 2021-11-30 | $2.6M | $1.1M | +77.72% |
| Q3 2021 · Sep 30 | 2021-09-30 | $2.2M | — | — |
| Q3 2021 · Jun 30 | 2021-06-30 | $2.3M | — | — |
| Q3 2021 · May 31 | 2021-05-31 | $2.3M | $1.3M | +136.64% |
| Q2 2021 · Mar 31 | 2021-03-31 | $1.7M | — | — |
| Q2 2021 · Feb 28 | 2021-02-28 | $1.9M | $496,975 | +36.26% |
| Q1 2021 | 2020-11-30 | $1.4M | $99,552 | +7.45% |
| Q4 2020 | 2020-08-31 | $1.0M | $74,202 | +7.78% |
| Q3 2020 | 2020-05-31 | $951,395 | $10,107 | +1.07% |
| Q2 2020 | 2020-02-29 | $1.4M | $612,615 | +80.83% |
| Q1 2020 | 2019-11-30 | $1.3M | $779,545 | +139.98% |
| Q4 2019 | 2019-08-31 | $953,421 | $263,308 | +38.15% |
| Q3 2019 | 2019-05-31 | $941,288 | $363,431 | +62.89% |
| Q2 2019 | 2019-02-28 | $757,919 | −$40,545 | −5.08% |
| Q1 2019 | 2018-11-30 | $556,903 | $279,846 | +101.01% |
| Q4 2018 | 2018-08-31 | $690,113 | $574,561 | +497.23% |
| Q3 2018 | 2018-05-31 | $577,857 | $482,132 | +503.66% |
| Q2 2018 | 2018-02-28 | $798,464 | $786,469 | +6556.64% |
| Q1 2018 | 2017-11-30 | $277,057 | $267,540 | +2811.18% |
| Q4 2017 | 2017-08-31 | $115,552 | $111,221 | +2568.02% |
| Q3 2017 | 2017-05-31 | $95,725 | $90,675 | +1795.54% |
| Q2 2017 | 2017-02-28 | $11,995 | $6,905 | +135.66% |
| Q1 2017 | 2016-11-30 | $9,517 | −$5,702 | −37.47% |
| Q4 2016 | 2016-08-31 | $4,331 | −$260 | −5.66% |
| Q3 2016 | 2016-05-31 | $5,050 | $2,550 | +102.00% |
| Q2 2016 | 2016-02-29 | $5,090 | −$1,060 | −17.24% |
| Q1 2016 | 2015-11-30 | $15,219 | $13,219 | +660.95% |
| Q4 2015 | 2015-08-31 | $4,591 | — | — |
| Q3 2015 | 2015-05-31 | $2,500 | −$5,650 | −69.33% |
| Q2 2015 | 2015-02-28 | $6,150 | −$445 | −6.75% |
| Q1 2015 | 2014-11-30 | $2,000 | — | — |
| Q3 2014 | 2014-05-31 | $8,150 | — | — |
| Q2 2014 | 2014-02-28 | $6,595 | — | — |
Artelo Biosciences operating expenses trends
Between the periods ended 2014-08-31 and 2025-12-31, Artelo Biosciences's operating expenses increased from $15,269 to $11.4M, a change of $11.4M. The latest reported quarter, Q2 2026, shows $2.5M.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Artelo Biosciences source filings ↗